Triclabendazole

Triclabendazole
Clinical data
Trade names	Fasinex, Egaten, others
AHFS/Drugs.com	Monograph
MedlinePlus	a619048
License data	US DailyMed: Triclabendazole;
Routes of; administration	By mouth
ATC code	P02BX04 (WHO) QP52AC01 (WHO);
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Metabolism	Oxidation to sulfone and sulfoxide metabolites
Elimination half-life	22–24 hours
Excretion	Feces (>95%), urine (2%), milk (<1%)
Identifiers
	IUPAC name 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole;
CAS Number	68786-66-3 ;
PubChem CID	50248;
DrugBank	DB12245 ;
ChemSpider	45565 ;
UNII	4784C8E03O;
KEGG	D07364 ;
ChEMBL	ChEMBL1086440 ;
CompTox Dashboard (EPA)	DTXSID7043952 ;
ECHA InfoCard	100.127.414
Chemical and physical data
Formula	C14H9Cl3N2OS
Molar mass	359.65 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	175 to 176 °C (347 to 349 °F)
	SMILES CSc3nc2cc(Cl)c(Oc1cccc(Cl)c1Cl)cc2[nH]3;
	InChI InChI=1S/C14H9Cl3N2OS/c1-21-14-18-9-5-8(16)12(6-10(9)19-14)20-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19) ; Key:NQPDXQQQCQDHHW-UHFFFAOYSA-N ;
	(what is this?) (verify)

Triclabendazole, sold under the brand name Egaten among others, is a medication used to treat fascioliasis and paragonimiasis.^[1] It is very effective for both conditions.^[1] Treatment in hospital may be required.^[1] It is taken by mouth with typically one or two doses being required.^[1]

Side effects are generally few, but can include abdominal pain and headaches.^[1] Biliary colic may occur due to dying worms.^[2] While no harm has been found with use during pregnancy, triclabendazole has not been studied well in this population.^[2] It is a member of the benzimidazole family of medications for worms.^[1]

Triclabendazole was approved for medical use in the United States in 2019.^[3]^[4] It is on the World Health Organization's List of Essential Medicines.^[5] For human use, it can be obtained from the World Health Organization.^[2] It is also used in animals.^[6]

^ ^a ^b ^c ^d ^e ^f World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 94, 96. hdl:10665/44053. ISBN 9789241547659.
^ ^a ^b ^c Wolfe MM, Lowe RC (2014). "Benzimidazoles". Pocket Guide to GastrointestinaI Drugs. John Wiley & Sons. p. PT173. ISBN 9781118481554. Archived from the original on 20 December 2016.
^ "Drug Trials Snapshots: Egaten". U.S. Food and Drug Administration (FDA). 13 February 2019.
^ "Egaten (triclabendazole)" (PDF). FDA. Archived from the original (PDF) on 2 October 2019. Retrieved 18 February 2019.
^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^ "Triclabendazole". Drugs.com. Archived from the original on 20 December 2016. Retrieved 10 December 2016.

[WHO2008-1] ^ ^a ^b ^c ^d ^e ^f World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 94, 96. hdl:10665/44053. ISBN 9789241547659.

[Mic2014-2] Wolfe MM, Lowe RC (2014). "Benzimidazoles". Pocket Guide to GastrointestinaI Drugs. John Wiley & Sons. p. PT173. ISBN 9781118481554. Archived from the original on 20 December 2016.

[3] "Drug Trials Snapshots: Egaten". U.S. Food and Drug Administration (FDA). 13 February 2019.

[4] "Egaten (triclabendazole)" (PDF). FDA. Archived from the original (PDF) on 2 October 2019. Retrieved 18 February 2019.

[WHO21st-5] World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[6] "Triclabendazole". Drugs.com. Archived from the original on 20 December 2016. Retrieved 10 December 2016.

[1]

[2]

[3]

[4]

[5]

[6]